3/9
11:37 am
ntla
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory [Seeking Alpha]
Low
Report
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory [Seeking Alpha]
3/8
06:02 pm
ntla
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? [Yahoo! Finance]
Medium
Report
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? [Yahoo! Finance]
3/6
04:44 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/6
04:01 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5
06:31 am
ntla
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound [Yahoo! Finance]
Medium
Report
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound [Yahoo! Finance]
3/4
08:00 am
ntla
Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.
Medium
Report
Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.
3/3
03:20 pm
ntla
Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
3/3
12:11 pm
ntla
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
Medium
Report
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
3/3
11:24 am
ntla
Intellia Therapeutics (NTLA) had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an "outperform" rating on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an "outperform" rating on the stock.
3/3
10:46 am
ntla
Intellia Therapeutics (NTLA) had its price target raised by Royal Bank Of Canada from $9.00 to $15.00. They now have a "sector perform" rating on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its price target raised by Royal Bank Of Canada from $9.00 to $15.00. They now have a "sector perform" rating on the stock.
3/3
10:18 am
ntla
Intellia Therapeutics (NTLA) had its price target raised by Wells Fargo & Company from $12.00 to $15.00. They now have an "equal weight" rating on the stock.
Medium
Report
Intellia Therapeutics (NTLA) had its price target raised by Wells Fargo & Company from $12.00 to $15.00. They now have an "equal weight" rating on the stock.
3/3
08:03 am
ntla
Intellia Therapeutics (NTLA) had its price target raised by HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Intellia Therapeutics (NTLA) had its price target raised by HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
3/3
08:03 am
ntla
Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $21.00 to $28.00. They now have a "market outperform" rating on the stock.
Medium
Report
Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $21.00 to $28.00. They now have a "market outperform" rating on the stock.
3/3
07:55 am
ntla
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 [Yahoo! Finance]
3/3
07:30 am
ntla
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Medium
Report
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
3/2
01:05 pm
ntla
Intellia Therapeutics (NTLA) had its "neutral" rating reaffirmed by Bank of America Corporation.
Low
Report
Intellia Therapeutics (NTLA) had its "neutral" rating reaffirmed by Bank of America Corporation.
3/2
01:00 pm
ntla
Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".
Low
Report
Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".
3/2
07:30 am
ntla
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Medium
Report
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
3/1
06:27 am
ntla
Intellia Advances Gene Editing Programs Toward Hereditary Angioedema Commercial Reality [Yahoo! Finance]
High
Report
Intellia Advances Gene Editing Programs Toward Hereditary Angioedema Commercial Reality [Yahoo! Finance]
2/28
10:25 am
ntla
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory [Yahoo! Finance]
High
Report
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory [Yahoo! Finance]
2/28
02:39 am
ntla
Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results [Yahoo! Finance]
2/27
07:03 pm
ntla
Intellia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Intellia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/27
08:32 am
ntla
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
2/26
09:55 pm
ntla
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/26
03:03 pm
ntla
Intellia (NTLA) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Intellia (NTLA) Q4 2025 Earnings Call Transcript [Yahoo! Finance]